Gene Therapy & Genetic Medicine

Big pharma M&A is aggressively restocking gene and cell therapy pipelines

Large pharma acquirers spent over $13 billion consolidating genetic medicine assets in the past 90 days: J&J acquired Sail Biomedicines for $785M and Firefly Bio for $1B, Novartis acquired Myricx Bio for $1.5B, and GSK took out Nuvalent for $10.6B at a 40% premium. This acquisition velocity is being explicitly fueled by GLP-1 cash flows — Eli Lilly alone announced more than $20B in acquisitions in 2026 — which are being recycled into pipeline restocking across gene therapy, cell therapy, and related modalities. Kelonia Therapeutics' $7B acquisition by Eli Lilly for its iGPS® in vivo CAR-T platform further underscores that proprietary delivery mechanisms command the highest strategic premiums.

SonoThera's $125M Series B — backed by a broad syndicate including Leaps by Bayer, Otsuka Pharmaceutical, J&J Innovation, ARK, RA Capital, Illumina Ventures, and UCB Ventures — signals that ultrasound-mediated nonviral gene delivery is graduating from academic novelty to institutional conviction. Analysts covering the round explicitly noted that nonviral delivery is approaching a critical validation inflection point, with the breadth of strategic and financial investors spanning pharma, genomics, and crossover funds as the key evidence. This mirrors broader industry momentum to sidestep the immunogenicity and manufacturing constraints of viral vectors.

Why it matters · A successful clinical readout for nonviral delivery would de-risk an entirely new therapeutic modality and redirect substantial capital away from AAV-dependent platforms.

Chan Zuckerberg Biohub received $500M in growth funding from CZI to build hierarchical world models of biology — proteins to cells to whole systems — with its ESM Atlas having already mapped 6.8 billion proteins and ESM Fold 2 folding 1.1 billion proteins and producing nanomolar antibody binders as an emergent property. Cell by Gene, CZI's open single-cell RNA annotation platform, has become a foundational corpus for transcriptomic AI models, and CZI's partnership with Jennifer Doudna on a CRISPR Cures program at UCSF links these computational capabilities directly to clinical translation. General Catalyst seeded both Vevo Therapeutics and Tahoe Therapeutics — building AI-native in vivo data atlases — signaling that the seed layer of the stack is also being funded.

Why it matters · Investors who back the foundational data and model infrastructure layer will capture leverage across every downstream therapeutic program that depends on it, making this the highest-optionality position in the genetic medicine stack.

CHOP's delivery of the first personalized CRISPR therapeutic to 'baby KJ' — targeting liver cells for a rare metabolic disease — was cited on the No Priors podcast as a landmark moment for gene editing clinical translation. CZI's active CRISPR Cures program with Jennifer Doudna at UCSF is now working to systematize that translation pathway. The week of July 13 saw $945M deployed across 3 deals, reflecting the capital market's response to these clinical signals.

Why it matters · Academic proof-of-concept in personalized CRISPR now creates a replicable template for commercial programs, compressing the timeline between discovery and IND-enabling studies.

Kelonia Therapeutics' $7B acquisition by Eli Lilly for its iGPS® lentiviral in vivo CAR-T platform — delivering a one-time injection that reprograms T-cells inside the body — represents the highest-value validation yet for in vivo gene delivery as a therapeutic modality. Nuvalent's $10.6B GSK acquisition and the J&J–Sail Biomedicines deal further demonstrate that pharma is willing to pay top-decile premiums for platforms with novel delivery mechanisms. Candid Therapeutics' $370M raise and subsequent UCB acquisition reinforce that the capital-to-acquisition pipeline for innovative delivery platforms is accelerating.

Why it matters · In vivo delivery platforms with proprietary vector or reprogramming technology are now the most acquisable asset class in biotech, and early-stage companies in this space face a compressed window before strategic buyers lock up the category.